Caravan Industry Association of Australia is proud to announce Pankind – Pancreatic Cancer Australia as the official Charity Partner for the 2026 Caravan Industry National Conference.
Our goal is to raise $100,000 to fund a groundbreaking early detection research project for pancreatic cancer.
Read on to learn more about this important cause and discover how you can make a difference at this year’s event.
In March 2025, long-standing caravan and camping industry leader Dave McIvor received life-changing news.
A respected park operator and a familiar face across the sector, Dave had been diagnosed with pancreatic cancer.
Pancreatic cancer is one of the toughest cancers. It is currently the third biggest cause of cancer death in Australia, claiming 78 lives every week. Sadly, survival rates remain among the lowest of any major cancer.
For many people, the disease is discovered too late, when treatment options are limited.
But Dave’s story is different.
Dave was diagnosed early, almost by chance. He had visited his doctor for an unrelated issue when further investigations revealed pancreatic cancer.
Early diagnosis gave Dave an opportunity that many people don’t receive. In mid-2025 he underwent a Whipple procedure, followed by multiple rounds of chemotherapy. The treatment was gruelling but it worked.
Today, Dave is in remission. In a disease where around 80 per cent of people do not survive beyond the first year, Dave knows how fortunate he has been.
He also knows why. Early detection made the difference.
Research shows that when pancreatic cancer is detected early, long-term survival can be up to 14 times higher than when it is diagnosed after the disease has spread.
That insight has become Dave’s mission.
Following his diagnosis, Dave approached Pankind – Pancreatic Cancer Australia with a clear goal. He wanted Australia’s caravan and camping industry to help change the story of pancreatic cancer.
In 2025, Caravan Industry Association of Australia partnered with Pankind at the National Conference to honour Dave’s experience and raise awareness of pancreatic cancer.
An industry-wide silent auction at the conference’s gala dinner raised $60,000 to support pancreatic cancer research.
For a disease that has historically received the lowest funding of any major cancer, this level of support is incredibly meaningful.
Those funds helped contribute to Pankind’s largest ever private investment in pancreatic cancer research in 2025, supporting projects focused on earlier detection and better treatment options.
Pankind is focused on improving survival by supporting:
Research supported by the caravan industry includes innovative work such as funding pioneering research led by scientists at the QIMR Berghofer Medical Research Institute to identify simple blood markers that could detect pancreatic cancer earlier, giving more people the chance for treatment when it can make the biggest difference.
Because pancreatic cancer receives limited government funding, advances in this disease rely heavily on community partners, industry supporters and philanthropic investment.
Pankind is once again the official Charity Partner of the Caravan Industry National Conference in 2026.
This year, the goal is ambitious. The charity hopes to raise $100,000 to fund a new pancreatic cancer early detection research project for 2026–2027.
By supporting this initiative, the caravan industry is helping accelerate progress toward Pankind’s mission to triple pancreatic cancer survival by 2030 and improve quality of life for those impacted by the disease.
There are several ways exhibitors and delegates can get involved:
Contribute an item or experience to be included in the conference raffle or gala dinner silent auction.
Prizes can range from:
Contact conference@caravanindustry.com.au to arrange your donation.
Support the mission directly through a tax-deductible contribution.
Contact conference@caravanindustry.com.au to arrange your donation.
Take part in the silent auction, try your luck in the raffle, or make a pledge during the evening.
Every contribution helps accelerate progress in early detection and treatment.
Every step forward gives more people the opportunity Dave had — the chance to be diagnosed early and access life-saving care.